Liraglutide, a human glucagon-like peptide 1 (GLP-1) analogue with high homology to native GLP-1, has structural modifications sufficient to amend pharmacokinetics for once-daily administration without compromising biological activity. Data from large, controlled, clinical studies have confirmed the therapeutic profile of liraglutide, with robust reductions in HbA1c, low risk of hypoglycaemia and clinically relevant reductions in body weight and systolic blood pressure. © 2008 Elsevier Ireland Ltd. All rights reserved.
Russell-Jones, D. (2009). Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Molecular and Cellular Endocrinology, 297(1–2), 137–140. https://doi.org/10.1016/j.mce.2008.11.018